Brief Title
Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)
Official Title
Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)
Brief Summary
Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear.
Detailed Description
Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear. It would involve an alteration of striatal-cortico-thalamic cortical circuits resulting in dopaminergic dysfunction. But glutamatergic hypothesis is also discussed from pharmacological, biochemical and genetic arguments. Exploration of glutamatergic system can be done in humans in vivo using a new radiotracer: the [18F] FNM (Fluoroethylnormemantine), a derivative of memantine. In the present study, aim of the study 1) to show the glutamatergic system "in vivo" in patients with Tourette's syndrome and 2) to perform correlations between various motor and behavioral symptoms and the pattern of brain fixation for this radiotracer. To do that, a pilot study will be conducted in 12 patients with Tourette's who will be evaluated in terms of motor (tics) and behavioral (OCD, anxiety, depression, impulsivity) symptoms. Each patient will have a PET-scan exam and a brain MRI exam. Data analysis will be carried out from two different approaches: first by region of interest, and secondly, without topographic a priori with the Statistical Parametric Mapping (SPM) software.
Study Type
Interventional
Primary Outcome
Correlation coefficients
Secondary Outcome
Yale Global Tic Severity Scale (YGTSS)
Condition
Tourette Syndrome
Intervention
Experimental MRI exam and PET scan exam with radiotracer
Study Arms / Comparison Groups
patient
Description: patients with Gilles de la Tourette syndrome
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Diagnostic Test
Estimated Enrollment
24
Start Date
November 26, 2018
Completion Date
December 2022
Primary Completion Date
December 2021
Eligibility Criteria
Inclusion Criteria: - Gilles de la Tourette syndrome according to the American Psychiatric association criteria (5 th ed, American Psychiatric association (APA), 2013) - Aged 18 and over - Patients treated with 2nd-generation neuroleptics for at least 3months - Signed consent form Exclusion Criteria: - contraindications for MRI exam - claustrophobia - person under exclusive period for another study - pregnant women - patients under non-authorized treatment (1rst generation neuroleptics) or non-treated by neuroleptics
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Christine BREFEL-COURBON, MD, 05 61 77 94 91, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT03681795
Organization ID
15 7836 03
Secondary IDs
2017-000816-40
Responsible Party
Sponsor
Study Sponsor
University Hospital, Toulouse
Study Sponsor
Christine BREFEL-COURBON, MD, Principal Investigator, University Hospital, Toulouse
Verification Date
August 2021